Compare Apartment Investment and Management Co (AIV) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apartment Investment and Management Co vs Gilead Sciences, Inc. — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $380.52M), while Gilead Sciences, Inc. trades at $135 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 433.6× Apartment Investment and Management Co's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Apartment Investment and Management Co pays none. Which is the better fit depends on your goals.
| AIV | GILD | |
|---|---|---|
Market Cap | $380.52M | $164.99B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $155.80 |
52-Week Low | $2.59 | $110.56 |
Enterprise Value | $742.67M | $188.06B |
Dividend Yield | — | 2.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
